No Data
No Data
Chardan Capital Maintains Buy on Cognition Therapeutics, Lowers Price Target to $8
Cognition Therapeutics Analyst Ratings
Earnings Call Summary | Cognition Therapeutics(CGTX.US) Q4 2024 Earnings Conference
COGNITION THERAPEUTICS Earnings Results: $CGTX Reports Quarterly Earnings
Cognition Therapeutics | 10-K: FY2024 Annual Report
Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia With Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials